SCHEMBL157306

SCHEMBL157306

CCCCCCCCCCCO[C]=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 8/20 0.43
CA2 P00918 8/20 0.43
CA9 Q16790 7/20 0.43
LPAR3 Q9UBY5 3/20 0.43
CA12 O43570 3/20 0.43
CA7 P43166 3/20 0.43
CA14 Q9ULX7 3/20 0.43
LPAR1 Q92633 2/20 0.43
LPAR2 Q9HBW0 2/20 0.43
CA3 P07451 2/20 0.43
CA4 P22748 2/20 0.43
CA6 P23280 2/20 0.43
CA5A P35218 2/20 0.43
CA5B Q9Y2D0 2/20 0.43
NAAA Q02083 1/20 0.43
TSHR P16473 2/20 0.42
THRB P10828 2/20 0.42
RECQL P46063 2/20 0.41
CES2 O00748 1/20 0.41
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL55803 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL2855857 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL93201 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL2858733 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL2862726 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL68307 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL2855746 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL77312 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL2861027 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL104986 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 889 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024112705-A1 BORONIC ACID AND BORONATE COMPOSITIONS AND METHODS ELIMA THERAPEUTICS, INC. (US) 2024-05-30 WO claimed
US-7687118-B2 Photocrosslinkable materials ROLIC AG (CH) 2010-03-30 US claimed
US-7419620-B2 Dichroic mixtures ROLIC LTD C/O ROLIC TECHNOLOGIES LTD (CH) 2008-09-02 US claimed
EP-1385914-B1 DICHROIC MIXTURE ROLIC AG (CH) 2008-07-23 EP claimed
US-20080069968-A1 Photocrosslinkable Materials ROLIC AG (CH) 2008-03-20 US claimed
EP-1799791-A1 PHOTOCROSSLINKABLE MATERIALS Rolic AG (CH) 2007-06-27 EP claimed
EP-1095947-B1 NOVEL ANTIBACTERIAL COMPOUNDS SANKYO CO (JP) 2007-03-14 EP claimed
WO-2006039824-A1 PHOTOCROSSLINKABLE MATERIALS ROLIC AG (CH) 2006-04-20 WO claimed
US-20040164272-A1 Dichoric mixture ROLIC AG (CH) 2004-08-26 US claimed
US-6762180-B1 Substituted indolines which inhibit receptor tyrosine kinases BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-07-13 US claimed
EP-1385914-A1 DICHROIC MIXTURE Rolic AG (CH) 2004-02-04 EP claimed
EP-1319406-A1 Novel antibacterial compounds Sankyo Company, Limited (JP) 2003-06-18 EP claimed
US-20030069204-A1 Strain of streptomyces SANKYO COMPANY LIMITED (JP) 2003-04-10 US claimed
US-20030064954-A1 Cationic amphiphilic 1,4-dihydropyridine derivatives useful for delivery of nucleotide containing compounds SPONDULI SERVICES, LTD. (AU) 2003-04-03 US claimed
EP-1261731-A1 CATIONIC AMPHIPHILIC 1,4-DIHYDROPYRIDINE DERIVATIVES USEFUL FOR DELIVERY OF NUCLEOTIDE CONTAINING COMPOUNDS Urtti, Arto (FI) 2002-12-04 EP claimed
WO-2002090447-A1 DICHROIC MIXTURE ROLIC AG (CH) 2002-11-14 WO claimed
EP-1256602-A1 Dichroic mixture Rolic AG (CH) 2002-11-13 EP claimed
US-6472384-B1 Antimicrobial compounds SANKYO COMPANY, LIMITED (JP) 2002-10-29 US claimed
WO-2001062946-A1 CATIONIC AMPHIPHILIC 1,4-DIHYDROPYRIDINE DERIVATIVES USEFUL FOR DELIVERY OF NUCLEOTIDE CONTAINING COMPOUNDS URTTI ARTO (FI) 2001-08-30 WO claimed
EP-1095947-A1 NOVEL ANTIBACTERIAL COMPOUNDS Sankyo Company Limited (JP) 2001-05-02 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064954-A1 Cationic amphiphilic 1,4-dihydropyridine derivatives useful for delivery of nucleotide containing compounds ACIN1, DNA2, KPNA1 CA1 3196/4885CA2 1934/4885CA9 3854/4885
US-20080069968-A1 Photocrosslinkable Materials PARG, VSIR, IGLV6-57 CA1 882/4885CA2 3560/4885CA9 1459/4885
US-20030069204-A1 Strain of streptomyces O60361, CYP8B1, MRPS34 CA1 4353/4885CA2 3197/4885CA9 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.